Vectibix 100mg Solution for Infusion
Marketer
Dr Reddy's Laboratories Ltd
Salt Composition
Panitumumab (100mg)
Overview Vectibix 100mg Solution for Infusion
Panitumumab 100mg intravenous solution is indicated for colorectal cancer treatment. It targets cancer cells, facilitating their destruction by the body's natural defenses. Administered intravenously under medical supervision, the dosage and frequency are determined by your physician based on your condition and may vary. Adhere strictly to your doctor's instructions; incorrect usage or overdose can cause severe adverse reactions. Therapeutic effects may take weeks or months to manifest; discontinue only under your doctor's guidance. Common side effects include nausea, vomiting, hypomagnesemia, and sleep disturbances. Report any concerning symptoms to your doctor; management strategies may be available. Photosensitivity is a potential side effect; protective clothing and sunscreen are recommended. Inform your healthcare provider about all medications you are taking, as interactions may occur. This medication is contraindicated during pregnancy and breastfeeding; effective contraception is crucial for both partners throughout treatment. Regular blood tests to monitor blood cell counts, cardiac function, liver health, and uric acid levels are necessary.
Primary Ingredients of Vectibix 100mg Solution for Infusion
There is no text provided to rephrase.
Uses of Vectibix 100mg Solution for Infusion
Colorectal cancer
Major Benefits of Vectibix 100mg Solution for Infusion:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
Common Side effects of Vectibix 100mg Solution for Infusion:
- Nausea
- Vomiting
- Decreased magnesium level in blood
- Insomnia (difficulty in sleeping)
- Diarrhea
- Cough
- Stomatitis (Inflammation of the mouth)
- Abdominal pain
- Constipation
- Decreased potassium level in blood
How to use Vectibix 100mg Solution for Infusion:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Vectibix 100mg Solution for Infusion works:
Panitumumab 100mg, administered intravenously, is a targeted therapy that selectively attaches to cancer cell surface receptors, marking them for elimination by the patient's own immune defenses.
SAFETY ADVICE
AlcoholUNSAFE
Combining Vectibix 100mg Infusion Solution and alcohol is not advisable due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
Panitumumab 100mg intravenous solution might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing. Patient consultation with their doctor is advised.
Breast feedingUNSAFE
Panitumumab 100mg injectable solution is contraindicated during lactation. Available evidence indicates potential infant harm from this medication.
DrivingUNSAFE
Panitumumab 100mg infusion may induce adverse reactions impacting driving capabilities. Patients experiencing vision changes and/or impaired concentration or reaction time due to therapy should refrain from operating vehicles or machinery until these effects resolve.
KidneySAFE IF PRESCRIBED
Panitumumab 100mg intravenous solution is likely safe for individuals with impaired renal function. Existing evidence indicates dose modification of Panitumumab 100mg intravenous solution may be unnecessary in this population. Physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Panitumumab 100mg intravenous solution is likely safe for patients with hepatic impairment. Preliminary findings indicate that dose modification may not be necessary. Physician consultation is advised.
What if you forget to take Vectibix 100mg Solution for Infusion :
Should you omit a scheduled dose of Vectibix 100mg intravenous solution, seek advice from your physician.
Facts to Know About Vectibix 100mg Solution for Infusion
| Label | Value |
|---|---|
| Chemical Type | Monoclonal antibody |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Action Class | Monoclonal antibody EGFR (ErbB1/HER1) inhibitors |
3,018 People bought this recently